Suppr超能文献

细针穿刺抽吸样本中弥漫性大B细胞淋巴瘤的CD10、BCL6和MUM1表达情况

CD10, BCL6, and MUM1 expression in diffuse large B-cell lymphoma on FNA samples.

作者信息

Cozzolino Immacolata, Varone Valeria, Picardi Marco, Baldi Carlo, Memoli Domenico, Ciancia Giuseppe, Selleri Carmine, De Rosa Gaetano, Vetrani Antonio, Zeppa Pio

机构信息

Department of Public Health, University of Naples "Federico II, " Naples, Italy.

Department of Advanced Biomedical Sciences, University of Naples "Federico II, " Naples, Italy.

出版信息

Cancer Cytopathol. 2016 Feb;124(2):135-43. doi: 10.1002/cncy.21626. Epub 2015 Sep 28.

Abstract

BACKGROUND

Gene expression profiling has divided diffuse large B-cell lymphoma (DLBCL) into 2 main subgroups: germinal center B (GCB) and non-GCB type. This classification is reproducible by immunohistochemistry using specific antibodies such as CD10, B-cell lymphoma 6 (BCL6), and multiple myeloma oncogene 1 (MUM1). Fine-needle aspiration (FNA) plays an important role in the diagnosis of non-Hodgkin lymphoma, and in some cases FNA may be the only available pathological specimen. The objectives of the current study were to evaluate CD10, BCL6, and MUM1 immunostaining on FNA samples by testing the CD10, BCL6, and MUM1 algorithm on both FNA cell blocks (CB) and conventional smears (CS), evaluating differences in CB and CS immunocytochemical (ICC) performance, and comparing results with histological data.

METHODS

Thirty-eight consecutive DLBCL cases diagnosed by FNA were studied. Additional passes were used to prepare CB in 22 cases and CS in 16 cases; the corresponding sections and smears were immunostained using CD10, BCL6, and MUM1 in all cases. The data obtained were compared with histological immunostaining in 24 cases.

RESULTS

ICC was successful in 33 cases (18 CB and 15 CS) and not evaluable in 5 cases (4 CB and 1 CS). The CD10-BCL6-MUM1 algorithm subclassified DLBCL as GCB (9 cases) and non-GCB (24 cases). ICC data were confirmed on histologic staining in 24 cases.

CONCLUSIONS

CD10, BCL6, and MUM1 ICC staining can be performed on FNA samples. The results herein prove it is reliable both on CB and CS, and is equally effective and comparable to immunohistochemistry data.

摘要

背景

基因表达谱分析已将弥漫性大B细胞淋巴瘤(DLBCL)分为两个主要亚组:生发中心B(GCB)型和非GCB型。这种分类可通过使用特定抗体(如CD10、B细胞淋巴瘤6(BCL6)和多发性骨髓瘤癌基因1(MUM1))的免疫组织化学方法重现。细针穿刺抽吸(FNA)在非霍奇金淋巴瘤的诊断中起着重要作用,在某些情况下,FNA可能是唯一可用的病理标本。本研究的目的是通过在FNA细胞块(CB)和传统涂片(CS)上测试CD10、BCL6和MUM1算法,评估FNA样本上的CD10、BCL6和MUM1免疫染色,评估CB和CS免疫细胞化学(ICC)性能的差异,并将结果与组织学数据进行比较。

方法

对38例经FNA诊断的连续DLBCL病例进行研究。另外取材制备22例CB和16例CS;所有病例的相应切片和涂片均使用CD10、BCL6和MUM1进行免疫染色。将获得的数据与24例病例的组织学免疫染色结果进行比较。

结果

33例(18例CB和15例CS)ICC成功,5例(4例CB和1例CS)不可评估。CD10-BCL6-MUM1算法将DLBCL分为GCB(9例)和非GCB(24例)。24例病例的ICC数据在组织学染色中得到证实。

结论

CD10、BCL6和MUM1 ICC染色可在FNA样本上进行。本文结果证明其在CB和CS上均可靠,且与免疫组织化学数据同样有效且具有可比性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验